Usefulness of FAMT-PET to predict the response after chemotherapy in patients withmalignant lymphoma

Usefulness of FAMT-PET to predict the response after chemotherapy in patients withmalignant lymphoma - FAMT-PET and prediction of chemotherapy in malignant lymphomna

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025980

Enrollment

Registered

2017-02-03

Start date

2017-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant lymphoma

Interventions

All patients undergo FAMT-PET/MRI before and 2 cycles after chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathologically confirmed malignant lymphoma, chemo-naive case. 2) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 3) Patient with evaluable lesion based on RECIST 4) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Pregnant woman 2) Patients with obvious interstitial pneumonia or pulmonary fibrosis in the chest X-ray. 3) Patients with collagen vascular disease or autoimmune diseases 4) Other cases attending physician it is determined unsuitable for registration of the study

Design outcomes

Primary

Measure	Time frame
Changeing of SUVmax, MTV and TLG, and the efficacy of chemotherapy Evaluation after 2 cycles from initial chemotherapy	—

Secondary

Measure	Time frame
Survival and adverse events	—

Countries

Japan

Contacts

Public ContactKyoichi Kaira

Gunma Univetsity Hospital Oncology Clinical Development

kkaira1970@yahoo.co.jp027-220-8222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026